Business Club, November 25th, core message: Hao Weizhe, chairman of the Pharmaceutical Group, revealed to reporters that Harbin Pharmaceuticals is investing in “rebuilding an international new Harbin medicine” and is making efforts to deepen the “natural medicine” market.

Compared to other pharmaceutical companies in China, which frequently launches the integration and acquisition of pharmaceutical assets, why is the pharmaceutical giant Ha Yao so low-key? A few days ago, Hao Yaozhe, chairman of the Harbin Pharmaceutical Group, revealed to reporters in Nandu City that Harbin Pharmaceuticals was investing in “rebuilding an international new Harbin medicine” and was making efforts to deepen the market of “natural medicines”.

Hao Weizhe told reporters that in the Chinese medicine industry, "subject medicine" is an industry term referring to Chinese herbal medicines with specific production areas, varieties, long history, mature production and processing technologies, and outstanding clinical efficacy. Hao Weizhe said that traditional Chinese medicine practitioners have strict requirements and restrictions on the selection of Chinese herbal medicines: they must choose authentic herbs. Because Chinese herbal medicines from different origins are affected by specific soil and climatic conditions, the quality is very different. The authenticity of medicinal herbs directly affects the quality of finished medicines. For this reason, Harbin Pharmaceuticals has always been pursuing the purpose of “being a real medicine and doing a good company” and deepening the market for farm products.

It is reported that at present Harbin Pharmaceutical Group has achieved three “super billions”, that is, the scale of assets exceeds 10 billion yuan, operating income exceeds 10 billion yuan, brand value exceeds 10 billion yuan, and has ranked among the top 100 pharmaceutical industries in China for 5 consecutive years. first.

Hao Weizhe said that according to the new strategic plan of Harbin Pharmaceutical Group, from the beginning of 2010, Harbin Pharmaceutical Group will implement a series of strategic transformation and upgrading plans to achieve a series of changes, "the eventual realization of Harbin Pharmaceutical Group's transformation from antibiotic to anti-infective drug field; The field of bio-engineering industry has changed to a large scale in various fields; the Chinese medicine industry has changed from traditional Chinese medicine to modernized Chinese medicine; the pharmaceutical industry has changed from a leading domestic company to a world-class pharmaceutical company, said Hao Weizhe.